Fresenius Medical initiated with a Buy at Goldman Sachs

Goldman Sachs analyst Richard Felton initiated coverage of Fresenius Medical Care with a Buy rating and EUR 56 price target. Fresenius has not seen meaningful positive consensus earnings revisions since January 2019, but that is about to change, the analyst tells investors in a research note. The firm believes an easing of external cost pressure and new management focused on driving improved performance under a new operating model can begin to drive an upgrade cycle.